<DOC>
	<DOCNO>NCT01945762</DOCNO>
	<brief_summary>This European multinational , multicenter , non-interventional ( observational ) prospective study . It carry confirm real life condition benefit/risk vandetanib ( CAPRELSA™ ) 300 mg , RET negative RET positive patient symptomatic , aggressive , sporadic , unresectable , locally advanced/metastatic MTC .</brief_summary>
	<brief_title>Observational Study Evaluate Vandetanib RET -/+ Patients With Metastatic Medullary Thyroid Cancer</brief_title>
	<detailed_description>This multinational , multicenter , non-interventional ( observational ) prospective study . European country vandetanib market participate study . This study conduct fulfil specific obligation post-authorisation measure conditional marketing authorisation . It carry confirm real life condition benefit/risk vandetanib ( CAPRELSA™ ) 300 mg , RET negative RET positive patient symptomatic , aggressive , sporadic , unresectable , locally advanced/metastatic MTC . The clinical benefit vandetanib ( CAPRELSA™ ) 300 mg previously establish clinical trial ( Study 58 ) basis clinically statistically significant advantage progression free survival ( PFS ) support high response rate substantial duration response .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>1 . Signed informed consent 2 . Male female age 18 year 3 . Histological diagnosis MTC 4 . Patients symptomatic aggressive sporadic MTC , unresectable , locally advanced/metastatic disease . ( The factor consider investigator determine patient 's disease symptomatic aggressive record CRF ) . 5 . Measurable disease : assessment confirm within 12 week previous start treatment , define accord RECIST 1.1 : least one lesion , irradiate , accurately measure ≥10 mm long diameter ( except lymph node must short axis ≥15 mm ) CT MRI suitable accurate repeat measurement . Measurable lesion calcification assess target lesion unless measurable lesion available . 6 . Known definite RET mutation status ( definition accord section 3.2 ) . The status : patient prescribe vandetanib : positive negative patient prescribe vandetanib : negative RET mutation status must determine tumour sample obtain within 18 month prior enrollment . It strongly recommend tissue sample obtain within 6 month prior enrolment use . 7 . For patient newly prescribe vandetanib 300 mg , prescription issue accord market authorisation follow vandetanib Summary Product Characteristics ( SmPC ) ( Appendix B ) . The start dose could reduce 200 mg patient moderate renal impairment Exclusion criterion 1 . Current plan inclusion/participation clinical trial 2 . Patients already receive vandetanib receive vandetanib MTC study first visit 3 . Contraindications accord vandetanib SmPC ( applicable patient receive vandetanib ) : ( ) Patients QT interval correct heart rate ( QTc ) interval 480 msec : ( ) Congenital long QT syndrome ( ii ) Concomitant use vandetanib follow medicinal product know also prolong QT interval / induce Torsades de pointes : Arsenic , cisapride , erythromycin intravenous ( IV ) , toremifene , mizolastine , moxifloxacin , Class I A III antiarrhythmic ( b ) Currently pregnant breast feeding ( c ) Hypersensitivity active substance excipients ( ) Severe renal impairment : creatinine clearance &lt; 30 ml/minute calculate CockcroftGault formula . ( See Appendix D ) . ( e ) Serum bilirubin great 1.5 x upper limit reference range ( ULRR ) ( f ) Potassium , magnesium calcium outside normal laboratory range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RET Mutation</keyword>
	<keyword>DIagnostics</keyword>
	<keyword>Medullary Thyroid Cancer</keyword>
	<keyword>MTC</keyword>
</DOC>